We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Blocking Glucose Metabolism Prevents Development of Metabolic Syndrome

By LabMedica International staff writers
Posted on 03 Sep 2018
A novel approach to preventing diabetes and other manifestations of metabolic syndrome, which includes obesity, diabetes, and fatty liver disease, showed promising results in mouse model systems.

The response by the liver to fasting has been proposed as a therapeutic pathway to enhance hepatic and whole-host metabolism. More...
However, the mechanisms underlying these metabolic effects remain unclear.

To help explain these mechanisms, investigators at Washington University School of Medicine (St. Louis, MO, USA) worked with various mouse models to evaluate the role of the enzyme epidermal-type lipoxygenase, eLOX3 (encoded by its gene, Aloxe3), as a potentially novel promotor of the therapeutic fasting response.

The investigators reported in the August 23, 2018, online edition of the journal JCI Insight that Aloxe3 was activated during fasting, glucose withdrawal, or trehalose/trehalose analogue treatment. Aloxe3 in the liver - whether activated by fasting or trehalose - improved the animals' insulin sensitivity as well as increasing calorie burning, raising body temperature, reducing weight gain and fat accumulation, and reducing levels of circulating fats and cholesterol in the blood.

In addition, administration of trehalose in the drinking water of mice fed an obesity-inducing diet protected the animals from developing metabolic disease. Although use of trehalose as a drug in humans is unlikely due to the ease in which it is broken down in the body, trehalose analogues such as lactotrehalose were found to demonstrate similar beneficial effects by activating Aloxe3 while not being as readily denatured.

"We learned that this gene, Aloxe3, improves insulin sensitivity in the same way that common diabetes drugs -- called thiazolidinediones -- improve insulin sensitivity," said senior author Dr. Brian DeBosch, assistant professor of pediatrics at Washington University School of Medicine. "And we showed that Aloxe3 activation in the liver is triggered by both trehalose and by fasting, possibly for the same reason: depriving the liver of glucose. In mice, this gene is turned on as part of what seems to be the normal fasting response. Our data suggest that fasting -- or giving trehalose with a normal diet -- triggers the liver to change the way it processes nutrients, in a beneficial way. And if glucose can be blocked from the liver with a drug, it may be possible to reap the benefits of fasting without strictly limiting food."

Related Links:
Washington University School of Medicine


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.